<VariationArchive VariationID="126217" VariationName="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs)" VariationType="Duplication" Accession="VCV000126217" Version="78" RecordType="classified" NumberOfSubmissions="26" NumberOfSubmitters="26" DateLastUpdated="2024-07-29" DateCreated="2014-04-04" MostRecentSubmission="2024-06-17">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="131755" VariationID="126217">
      <GeneList>
        <Gene Symbol="BRCA2" FullName="BRCA2 DNA repair associated" GeneID="675" HGNC_ID="HGNC:1101" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>13q13.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32315508" stop="32400268" display_start="32315508" display_stop="32400268" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32889616" stop="32973808" display_start="32889616" display_stop="32973808" Strand="+" />
          </Location>
          <OMIM>600185</OMIM>
          <Haploinsufficiency last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-07-14" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=BRCA2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs)</Name>
      <CanonicalSPDI>NC_000013.11:32398184:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>13q13.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="13" Accession="NC_000013.11" start="32398184" stop="32398185" display_start="32398184" display_stop="32398185" variantLength="1" positionVCF="32398184" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="13" Accession="NC_000013.10" start="32972321" stop="32972322" display_start="32972321" display_stop="32972322" variantLength="1" positionVCF="32972321" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
      </Location>
      <OtherNameList>
        <Name>9900insA</Name>
        <Name>p.Tyr3225IlefsX30</Name>
      </OtherNameList>
      <ProteinChange>Y3225fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.10" sequenceAccession="NC_000013" sequenceVersion="10" change="g.32972322dup" Assembly="GRCh37">
            <Expression>NC_000013.10:g.32972322dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000013.11" sequenceAccession="NC_000013" sequenceVersion="11" change="g.32398185dup" Assembly="GRCh38">
            <Expression>NC_000013.11:g.32398185dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012772.3" sequenceAccession="NG_012772" sequenceVersion="3" change="g.87706dup">
            <Expression>NG_012772.3:g.87706dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.4" sequenceAccession="NM_000059" sequenceVersion="4" change="c.9672dup" MANESelect="true">
            <Expression>NM_000059.4:c.9672dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000050.3" sequenceAccession="NP_000050" sequenceVersion="3" change="p.Tyr3225fs">
            <Expression>NP_000050.3:p.Tyr3225fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_293" sequenceAccession="LRG_293">
            <Expression>LRG_293:g.87706dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000059.3" sequenceAccession="NM_000059" sequenceVersion="3" change="c.9672dupA">
            <Expression>NM_000059.3:c.9672dupA</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="U43746.1" sequenceAccession="U43746" sequenceVersion="1" change="n.9900_9901insA">
            <Expression>U43746.1:n.9900_9901insA</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="9900&amp;base_change=ins A" DB="Breast Cancer Information Core (BIC) (BRCA2)" />
        <XRef ID="CA026263" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="600185.0019" DB="OMIM" />
        <XRef Type="rs" ID="80359773" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD), exomes" />
        <AlleleFrequency Value="0.00001" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND Fanconi anemia complementation group D1" Accession="RCV000009922" Version="13">
        <ClassifiedConditionList TraitSetID="2562">
          <ClassifiedCondition DB="MedGen" ID="C1838457">Fanconi anemia complementation group D1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2002-07-26" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND Breast-ovarian cancer, familial, susceptibility to, 2" Accession="RCV000114151" Version="20">
        <ClassifiedConditionList TraitSetID="2560">
          <ClassifiedCondition DB="MedGen" ID="C2675520">Breast-ovarian cancer, familial, susceptibility to, 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2016-09-08" SubmissionCount="9">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND Hereditary cancer-predisposing syndrome" Accession="RCV000130631" Version="20">
        <ClassifiedConditionList TraitSetID="13598">
          <ClassifiedCondition DB="MedGen" ID="C0027672">Hereditary cancer-predisposing syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-10-20" SubmissionCount="3">Pathogenic/Likely pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND Hereditary breast ovarian cancer syndrome" Accession="RCV000197712" Version="24">
        <ClassifiedConditionList TraitSetID="7920">
          <ClassifiedCondition DB="MedGen" ID="C0677776">Hereditary breast ovarian cancer syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-12-05" SubmissionCount="3">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND not provided" Accession="RCV000372727" Version="22">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-11-10" SubmissionCount="7">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND Malignant tumor of breast" Accession="RCV001353641" Version="10">
        <ClassifiedConditionList TraitSetID="25616">
          <ClassifiedCondition DB="MedGen" ID="C0006142">Malignant tumor of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND Familial cancer of breast" Accession="RCV003460795" Version="2">
        <ClassifiedConditionList TraitSetID="774">
          <ClassifiedCondition DB="MedGen" ID="C0346153">Familial cancer of breast</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-01-15" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000059.4(BRCA2):c.9672dup (p.Tyr3225fs) AND BRCA2-related disorder" Accession="RCV004529911" Version="1">
        <ClassifiedConditionList TraitSetID="33530">
          <ClassifiedCondition DB="MedGen" ID="CN239275">BRCA2-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-20" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2016-09-08" NumberOfSubmissions="26" NumberOfSubmitters="26" DateCreated="2014-04-04" MostRecentSubmission="2024-06-17">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10433620</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12065746</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16115142</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16683254</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16920162</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17026620</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17515903</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18593900</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18607349</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22711857</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22720145</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">22921157</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23531862</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24156927</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24312913</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25103822</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25452441</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26740091</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">26846091</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27153395</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">28152038</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29446198</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29753700</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">32341426</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="13598" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="18746" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary neoplastic syndrome</ElementValue>
                <XRef ID="MONDO:0015356" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Neoplastic Syndromes, Hereditary</ElementValue>
                <XRef ID="D009386" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Cancer Syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
                <XRef ID="699346009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Tumor predisposition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer predisposition</ElementValue>
                <XRef ID="Hereditary+Cancer/3345" DB="Genetic Alliance" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="19921" />
                <XRef ID="19921" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="general" Abbrev="IARC, 2008">
                <ID Source="pmc">3075918</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <XRef ID="140162" DB="Orphanet" />
              <XRef ID="C0027672" DB="MedGen" />
              <XRef ID="D009386" DB="MeSH" />
              <XRef ID="MONDO:0015356" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="25616" Type="Finding" ContributesToAggregateClassification="false">
            <Trait ID="34847" Type="Finding">
              <Name>
                <ElementValue Type="Preferred">Malignant tumor of breast</ElementValue>
                <XRef ID="254837009" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Malignant breast neoplasm</ElementValue>
                <XRef ID="C9335" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cancer breast</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="pmc">2936467</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2018">
                <ID Source="PubMed">29939840</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479144</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2019">
                <ID Source="PubMed">30452337</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2018">
                <URL>https://www.nice.org.uk/guidance/dg34</URL>
                <CitationText>Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/ng12</URL>
                <CitationText>UK NICE Guideline NG12, Suspected cancer: recognition and referral, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="C0006142" DB="MedGen" />
              <XRef ID="MONDO:0007254" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="7920" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="16761" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome</ElementValue>
                <XRef ID="D061325" DB="MeSH" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer syndrome (HBOC)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary breast ovarian cancer syndrome</ElementValue>
                <XRef ID="MONDO:0003582" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast and ovarian cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and/or ovarian cancer syndrome</ElementValue>
                <XRef ID="145" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary breast and ovarian cancer</ElementValue>
                <XRef ID="UWMG_4506306" DB="CSER _CC_NCGL, University of Washington" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HBOC</ElementValue>
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509978" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530118" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000500933" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522278" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530028" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522161" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551448" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512699" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021517" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017876" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000502103" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558910" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000595973" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501981" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508566" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508956" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508948" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551441" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552302" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325409" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520887" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509983" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551440" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521499" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509982" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522559" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561859" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000503369" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000514601" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552183" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000523320" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15010" />
                <XRef ID="15010" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2003">
                <ID Source="PubMed">12692171</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg122</URL>
                <CitationText>UK NICE Clinical guideline (CG122), Ovarian cancer: recognition and initial management, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C0677776" DB="MedGen" />
              <XRef ID="D061325" DB="MeSH" />
              <XRef ID="MONDO:0003582" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2562" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="1276" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group D1</ElementValue>
                <XRef ID="MONDO:0011584" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCD1</ElementValue>
                <XRef Type="MIM" ID="605724" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FAD1</ElementValue>
                <XRef Type="MIM" ID="605724" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17449" />
                <XRef ID="17449" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="Suggested Reading">
                <ID Source="PubMed">14559878</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management (3rd Ed.), 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/explore/clinical-care-guidelines</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="319462" DB="Orphanet" />
              <XRef ID="C1838457" DB="MedGen" />
              <XRef ID="MONDO:0011584" DB="MONDO" />
              <XRef Type="MIM" ID="605724" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="2560" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="636" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 2</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+2/7866" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 2</ElementValue>
                <XRef ID="MONDO:0012933" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BROVCA2</ElementValue>
                <XRef Type="MIM" ID="612555" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000531275" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509984" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000551447" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000017874" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528915" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000519030" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000505644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552245" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592961" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000552304" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509450" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512644" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520071" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509001" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520867" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000320777" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000332529" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000604264" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520072" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000326160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509002" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000527942" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509985" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507653" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509692" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530202" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522160" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501748" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000530120" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512645" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000509980" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000021468" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000330054" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507864" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520870" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520865" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000528916" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501818" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000507764" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520394" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520871" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000512816" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501744" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520869" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520872" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520866" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522159" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000325401" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569406" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520069" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACS, 2007">
                <ID Source="PubMed">17392385</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2010">
                <ID Source="PubMed">20065170</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2009">
                <ID Source="PubMed">19305347</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Phillips et al., 2013">
                <ID Source="PubMed">23918944</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="Domchek et al., 2010">
                <ID Source="pmc">2948529</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2013">
                <ID Source="pmc">3585492</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2013">
                <ID Source="PubMed">23188549</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2021">
                <ID Source="PubMed">33410258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2015">
                <ID Source="PubMed">26324357</ID>
              </Citation>
              <Citation Type="general" Abbrev="CAPS, 2020">
                <ID Source="PubMed">31672839</ID>
                <ID Source="pmc">7295005</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C2675520" DB="MedGen" />
              <XRef ID="MONDO:0012933" DB="MONDO" />
              <XRef Type="MIM" ID="612555" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="774" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="536" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Breast cancer, familial</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Familial cancer of breast</ElementValue>
                <XRef ID="Familial+cancer+of+breast/8375" DB="Genetic Alliance" />
                <XRef ID="254843006" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000530707" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000531340" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591268" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570011" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000561700" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000569423" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558503" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000562228" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17142" />
                <XRef ID="17142" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">BRCA1- and BRCA2-associated hereditary breast and ovarian cancer (HBOC) is characterized by an increased risk for female and male breast cancer, ovarian cancer (including fallopian tube and primary peritoneal cancers), and to a lesser extent other cancers such as prostate cancer, pancreatic cancer, and melanoma primarily in individuals with a BRCA2 pathogenic variant. The risk of developing an associated cancer varies depending on whether HBOC is caused by a BRCA1 or BRCA2 pathogenic variant.</Attribute>
                <XRef ID="NBK1247" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301425</ID>
                <ID Source="BookShelf">NBK1247</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="review" Abbrev="Stratton and Rahman, 2008">
                <ID Source="PubMed">18163131</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2007">
                <ID Source="PubMed">17508274</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014 [Archived]">
                <ID Source="PubMed">24366376</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2014">
                <ID Source="PubMed">24366402</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2013">
                <ID Source="PubMed">24432435</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Breast and Gynecologic Cancers">
                <ID Source="PubMed">26389210</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1419</URL>
                <CitationText>Breast Cancer, NCCN Guidelines Version 4.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2022">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology, Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic version 2.2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="St. Gallen, 2021">
                <ID Source="PubMed">34242744</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31429903</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="USPSTF, 2019">
                <ID Source="PubMed">31479213</ID>
                <ID Source="BookShelf">NBK545867</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Hereditary-Breast-Ovarian-Cancer.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, BRCA1 and BRCA2 Pathogenic Variants (Hereditary Breast and Ovarian Cancer), 2019</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2023">
                <URL>https://www.nice.org.uk/guidance/cg164</URL>
                <CitationText>UK NICE Clinical Guideline CG164, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NICE, 2024">
                <URL>https://www.nice.org.uk/guidance/ng101</URL>
                <CitationText>UK NICE Guideline NG101, Early and locally advanced breast cancer: diagnosis and management, 2024</CitationText>
              </Citation>
              <XRef ID="227535" DB="Orphanet" />
              <XRef ID="C0346153" DB="MedGen" />
              <XRef ID="MONDO:0016419" DB="MONDO" />
              <XRef Type="MIM" ID="114480" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33530" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="36472" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">BRCA2-Related Disorders</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">BRCA2-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">BRCA2-related disorder</ElementValue>
              </Name>
              <XRef ID="CN239275" DB="MedGen" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1449982" SubmissionDate="2018-04-17" DateLastUpdated="2018-04-19" DateCreated="2018-04-19">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000743528" DateUpdated="2018-04-19" DateCreated="2018-04-19" Type="SCV" Version="1" SubmitterName="Genome Diagnostics Laboratory, University Medical Center Utrecht" OrgID="274978" OrganizationCategory="laboratory" OrgAbbreviation="GDL-UMCU" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-10-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACGS Guidelines, 2013</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/zo8lkdib/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_finalpdf.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB3915625</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="30143" SubmissionDate="2017-11-28" DateLastUpdated="2018-05-21" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="600185.0019_FANCONI ANEMIA, COMPLEMENTATION GROUP D1" title="BRCA2, 1-BP INS, 9900A_FANCONI ANEMIA, COMPLEMENTATION GROUP D1" />
        <ClinVarAccession Accession="SCV000030143" DateUpdated="2018-05-21" DateCreated="2013-04-04" Type="SCV" Version="4" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-07-26">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In the Fanconi anemia complementation group D1 (FANCD1; 605724) reference cell line EUFA423, Howlett et al. (2002) found a 9900insA mutation in the BRCA2 gene in compound heterozygosity with 7691insAT (600185.0018). The 9900insA mutant allele was previously identified in a breast cancer kindred (Breast Cancer Linkage Consortium, 1999).</Attribute>
              <Citation>
                <ID Source="PubMed">12065746</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">10433620</ID>
              </Citation>
              <XRef DB="OMIM" ID="605724" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <Name>BRCA2, 1-BP INS, 9900A</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, 9900A</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="600185.0019" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">FANCONI ANEMIA, COMPLEMENTATION GROUP D1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5042042" SubmissionDate="2022-10-06" DateLastUpdated="2022-10-15" DateCreated="2022-10-15">
        <ClinVarSubmissionID localKey="NM_000059.4:c.9672dup|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002581551" DateUpdated="2022-10-15" DateCreated="2022-10-15" Type="SCV" Version="1" SubmitterName="MGZ Medical Genetics Center" OrgID="255845" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="80359773" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9672dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <Comment>ACMG criteria applied: PVS1, PS4, PM2_SUP, PP1</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB12035528</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="627268" SubmissionDate="2016-10-28" DateLastUpdated="2022-12-11" DateCreated="2016-11-05">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dup|OMIM:612555" submittedAssembly="hg18" />
        <ClinVarAccession Accession="SCV000328160" DateUpdated="2022-12-11" DateCreated="2016-11-05" Type="SCV" Version="4" SubmitterName="Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge" OrgID="505954" OrganizationCategory="consortium" OrgAbbreviation="CIMBA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-10-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CIMBA Mutation Classification guidelines May 2016</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/nhgqiuyb/cimba_mutation_classification_guidelines_may16.pdf</URL>
            <CitationText>CIMBA_Mutation_Classification_guidelines_May16.pdf</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="31" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>CIMBA_20161005</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8353352" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2024-02-20">
        <ClinVarSubmissionID localKey="4019662|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004563568" DateUpdated="2024-02-20" DateCreated="2024-02-20" Type="SCV" Version="1" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-10">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2 c.9672dup; p.Tyr3225IlefsTer30 variant (rs80359773), also known as 9900insA, is reported in multiple individuals and families with hereditary breast and ovarian cancer syndrome and found compound heterozygous in at least one individual with Fanconi anemia (de Jonge 2019, Howlett 2002, Verhoog 2001). This variant is classified as pathogenic by an expert panel in the ClinVar Database (Variation ID: 126217). It is only found on one allele in the Genome Aggregation Database (v2.1.1), indicating it is not a common polymorphism. This variant causes a frameshift by inserting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. This variant results in a premature termination codon in the last exon of the BRCA2 gene. While this may not lead to nonsense-mediated decay, it is expected to create a truncated BRCA2 protein. Based on available information, this variant is considered to be pathogenic. References: de Jonge MM et al. Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clin Cancer Res. 2019 Dec 15;25(24):7517-7526. PMID: 31492746. Howlett NG et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002 Jul 26;297(5581):606-9. PMID: 12065746. Verhoog LC et al. Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer. 2001 Nov;37(16):2082-90. PMID: 11597388.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972322dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7863313" SubmissionDate="2024-06-05" DateLastUpdated="2024-06-17" DateCreated="2023-12-30">
        <ClinVarSubmissionID localKey="NM_000059.4:c.9672dup|OMIM:114480" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004213675" DateUpdated="2024-06-17" DateCreated="2023-12-30" Type="SCV" Version="2" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-01-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9672dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="114480" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GA_HC_20231102_20240331</SubmissionName>
          <SubmissionName>SUB13856327</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="264594" SubmissionDate="2014-03-28" DateLastUpdated="2014-04-04" DateCreated="2014-04-04">
        <ClinVarSubmissionID localKey="U43746.1:n.9900_9901insA|MedGen:C2675520" />
        <ClinVarAccession Accession="SCV000147696" DateUpdated="2014-04-04" DateCreated="2014-04-04" Type="SCV" Version="1" SubmitterName="Breast Cancer Information Core (BIC) (BRCA2)" OrgID="504197" OrganizationCategory="locus-specific database (LSDB)" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2002-05-29">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <GeographicOrigin>Western European</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Caucasian</Ethnicity>
              <GeographicOrigin>Netherlands</GeographicOrigin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Ethnicity>Central/Eastern European</Ethnicity>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>U43746.1:exon 27</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>9900insA</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="dbSNP" ID="80359773" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">U43746.1:n.9900_9901insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Breast-ovarian cancer, familial 2</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C2675520" Type="CUI" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="502844" SubmissionDate="2016-04-21" DateLastUpdated="2014-04-04" DateCreated="2014-04-04">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000196029" DateUpdated="2014-04-04" DateCreated="2014-04-04" Type="SCV" Version="1" SubmitterName="Michigan Medical Genetics Laboratories, University of Michigan" OrgID="308659" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2014-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Tissue>Blood</Tissue>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="80359773" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="582455" SubmissionDate="2016-09-13" DateLastUpdated="2016-09-24" DateCreated="2016-09-24">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|OMIM:612555" submittedAssembly="not applicable" />
        <ClinVarAccession Accession="SCV000301407" DateUpdated="2016-09-24" DateCreated="2016-09-24" Type="SCV" Version="2" SubmitterName="Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)" OrgID="504863" OrganizationCategory="consortium" OrgAbbreviation="ENIGMA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-09-08">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Variant allele predicted to encode a truncated non-functional protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ENIGMA BRCA1/2 Classification Criteria (2015)</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/c2ffjci6/enigma_rules_2015-03-26.pdf</URL>
            <CitationText>ENIGMA BRCA1/2 Classification Criteria (2015)</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyDescription>ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles) is a consortium focused on determining the clinical significance of variants in BRCA1, BRCA2 and other known/suspected breast cancer genes. http://enigmaconsortium.org/</StudyDescription>
        <SubmissionNameList>
          <SubmissionName>ENIGMA_2016-09-13</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1414502" SubmissionDate="2018-04-04" DateLastUpdated="2018-04-09" DateCreated="2018-04-09">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000733341" DateUpdated="2018-04-09" DateCreated="2018-04-09" Type="SCV" Version="1" SubmitterName="Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen" OrgID="506382" OrganizationCategory="laboratory" OrgAbbreviation="DL-UMCG" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB3868021</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1553297" SubmissionDate="2018-05-23" DateLastUpdated="2017-10-21" DateCreated="2017-10-21">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000803165" DateUpdated="2017-10-21" DateCreated="2017-10-21" Type="SCV" Version="1" SubmitterName="Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C." OrgID="505776" OrganizationCategory="laboratory" OrgAbbreviation="IBR" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-05-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Hereditary cancer-predisposing syndrome</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>IBR-5-23-18</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1361613" SubmissionDate="2021-02-26" DateLastUpdated="2017-12-26" DateCreated="2017-12-26">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000695261" DateUpdated="2017-12-26" DateCreated="2017-12-26" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-02-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16115142</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22720145</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25452441</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16920162</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26846091</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29446198</ID>
          </Citation>
          <Comment>Variant summary: BRCA2 c.9672dupA (p.Tyr3225IlefsX30) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 249832 control chromosomes (gnomAD and publication). c.9672dupA has been reported in the literature in multiple individuals affected with breast cancer and/or ovarian cancer (Couch_2015, Rebbeck_2018, BIC database). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. 11 ClinVar submitters, including one expert panel (ENIGMA), (evaluation after 2014) cite the variant as pathogenic (n=10) and likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB9159508</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1148746" SubmissionDate="2021-03-31" DateLastUpdated="2021-04-13" DateCreated="2015-10-11">
        <ClinVarSubmissionID localKey="chr13:32972320-32972321:bdf9326388d4e9f43491641407bbf722-BREAST" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000592302" DateUpdated="2021-04-13" DateCreated="2015-10-11" Type="SCV" Version="2" SubmitterName="Department of Pathology and Laboratory Medicine, Sinai Health System" OrgID="506152" OrganizationCategory="laboratory" OrgAbbreviation="PLM-SHS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506759" SubmitterName="Franklin by Genoox" Type="secondary" OrganizationCategory="other" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2 p.Tyr3225IlefsX30 variant was identified in individuals with hereditary breast and ovarian cancer (Karami 2013, Vos 2014) in the Netherlands populations and in Fanconi Anemia patients (Barber 2005, Howlett 2002, Lee 2014, Offit 2003, Reid 2005Â¬Â¨, Wang 2004), although no frequency data was given. The variant was also identified in dbSNP (ID: rs80359773) as â€šÃ„ÃºWith Pathogenic alleleâ€šÃ„Ã¹, Clinvitae database (pathogenic, Invitae), ARUP Laboratories BRCA Mutations Database (as definitely pathogenic), the ClinVar database (pathogenic, by multiple submitters), GeneInsight COGR database (unclassified) the BIC database (4x with unknown clinical importance), and UMD (3x with a â€šÃ„Ãºcausalâ€šÃ„Ã¹ classification). The c.9672dupA variant is predicted to cause a frameshift, which alters the protein's amino acid sequence beginning at codon 3225 and leads to a premature stop codon at position 3254. This alteration is then predicted to result in a truncated or absent protein and loss of function. Loss of function variants of the BRCA2 gene are an established mechanism of disease in hereditary breast and ovarian cancer and is the type of variant expected to cause the disorder. In summary, based on the above information, this variant meets our laboratoryâ€šÃ„Ã´s criteria to be classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="TA" referenceAllele="T" start="32972321" stop="32972321" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007254" />
          </Trait>
        </TraitSet>
        <StudyName>The Canadian Open Genetics Repository (COGR)</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB9371647</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3746646" SubmissionDate="2021-09-20" DateLastUpdated="2021-09-26" DateCreated="2021-09-26">
        <ClinVarSubmissionID localKey=":Chr.13_32972321_32972321_T_TA|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001905702" DateUpdated="2021-09-26" DateCreated="2021-09-26" Type="SCV" Version="1" SubmitterName="Clinical Genetics Laboratory, Department of Pathology, Netherlands Cancer Institute" OrgID="506537" OrganizationCategory="clinic" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506382" SubmitterName="Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen" Type="behalf" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="TA" referenceAllele="T" start="32972321" stop="32972321" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB10399800</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="642938" SubmissionDate="2022-04-06" DateLastUpdated="2023-03-04" DateCreated="2016-12-06">
        <ClinVarSubmissionID localKey="GDXSV:223995" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV000329588" DateUpdated="2023-03-04" DateCreated="2016-12-06" Type="SCV" Version="7" SubmitterName="GeneDx" OrgID="26957" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-03-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Frameshift variant predicted to result in protein truncation in a gene for which loss of function is a known mechanism of disease; Published functional studies demonstrate a damaging effect: cell line with this variant exhibited sensitivity to MMC exposure, increased IR induction of foci (present in both cytoplasm and nucleus) and absent FANCD2/BRCA2 complex in chromatin (Wang 2004); Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants are considered pathogenic by a well-established clinical consortium and/or database.; Also known as c.9900dupA; This variant is associated with the following publications: (PMID: 24301060, 28152038, 24156927, 14559878, 16683254, 16115142, 25447315, 25452441, 15689453, 24312913, 11597388, 15645491, 22921157, 26846091, 26740091, 22720145, 29922827, 29446198, 29753700, 30720243, 30291343, 32341426, 30787465, 31076742, 35216584, 12065746, 15199141, 10733923, 9126738)</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">GeneDx Variant Classification Process June 2021</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/fc81e176/genedx_variant_classification_process_june_2021.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Duplication</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">GDX:259564</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Not Provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>GeneDX_Clinvar_Submission_51_20210925044204</SubmissionName>
          <SubmissionName>GeneDX_Clinvar_Submission_99_20220406054204</SubmissionName>
          <SubmissionName>SUB5098196</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1779302" SubmissionDate="2024-01-25" DateLastUpdated="2024-02-14" DateCreated="2019-05-19">
        <ClinVarSubmissionID localKey="Db4KrQBSZeoE7-orUyypkafDzbURSje0ojZrWrsi8mE|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000911347" DateUpdated="2024-02-14" DateCreated="2019-05-19" Type="SCV" Version="4" SubmitterName="Color Diagnostics, LLC DBA Color Health" OrgID="505849" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-10-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16920162</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17515903</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22720145</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25452441</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26740091</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27153395</ID>
          </Citation>
          <Comment>This variant inserts 1 nucleotide in codon 3225 in exon 27 of the BRCA2 gene, creating a frameshift and premature translation stop signal in the last coding exon. This variant is also known as 9900insA and c.9672_9673insA in the literature. This mutant transcript is predicted to escape nonsense-mediated decay and be expressed as a truncated protein. This variant is expected to disrupt the RAD51 binding domain that has been reported to be essential for homologous recombination and DNA repair (PMID: 17515903). Cell lines that are compound heterozygous for this variant and a known pathogenic BRCA2 truncation variant produced a truncated protein consistent with truncation in exon 27 (PMID: 12065746) and exhibited hypersensitivity to mitomycin C and other DNA damaging agents (PMID: 12065746, 16920162). This variant also has been reported in multiple individuals with personal or family history of breast and/or ovarian cancer (PMID: 16683254, 24156927, 25452441, 27153395, Color internal data). This variant has also been reported in three individuals who are compound heterozygous with a pathogenic BRCA2 covariant and affected with Fanconi anemia (PMID: 12065746, 22720145, 26740091). An external laboratory has reported the associated cancer histories of multiple carriers of this variant are inconsistent with known BRCA2 pathogenic variants (https://myriad-web.s3.amazonaws.com/publications/74925948-ACMG%202017%20Mundt%20variant%20classification%20Presented.pdf). This variant has been identified in 1/249592 chromosomes in the general population by the Genome Aggregation Database (gnomAD). In summary, this rare variant has been observed in multiple individuals and families affected with BRCA2-related phenotypes. Although additional studies are necessary to determine the role of this variant in disease and penetrance conclusively, this variant is classified as Likely Pathogenic based on the available evidence.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <TypePlatform>NGS</TypePlatform>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.4:c.9672dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>Color Genomics - ClinVar Submission - May2020 - SUB747</SubmissionName>
          <SubmissionName>SUB10906337</SubmissionName>
          <SubmissionName>SUB14171678</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9032961" SubmissionDate="2024-04-16" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="407032|MONDO:0012933" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004846215" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="All of Us Research Program, National Institutes of Health" OrgID="509529" OrganizationCategory="consortium" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-02-24">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Likely Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16920162</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17515903</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22720145</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25452441</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26740091</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27153395</ID>
          </Citation>
          <Comment>This variant inserts 1 nucleotide in codon 3225 in exon 27 of the BRCA2 gene, creating a frameshift and premature translation stop signal in the last coding exon. This variant is also known as 9900insA and c.9672_9673insA in the literature. This mutant transcript is predicted to escape nonsense-mediated decay and be expressed as a truncated protein. This variant is expected to disrupt the RAD51 binding domain that has been reported to be essential for homologous recombination and DNA repair (PMID: 17515903). Cell lines that are compound heterozygous for this variant and a known pathogenic BRCA2 truncation variant produced a truncated protein consistent with truncation in exon 27 (PMID: 12065746) and exhibited hypersensitivity to mitomycin C and other DNA damaging agents (PMID: 12065746, 16920162). This variant also has been reported in multiple individuals with personal or family history of breast and/or ovarian cancer (PMID: 16683254, 24156927, 25452441, 27153395, Color internal data). This variant has also been reported in three individuals who are compound heterozygous with a pathogenic BRCA2 covariant and affected with Fanconi anemia (PMID: 12065746, 22720145, 26740091). An external laboratory has reported the associated cancer histories of multiple carriers of this variant are inconsistent with known BRCA2 pathogenic variants (https://myriad-web.s3.amazonaws.com/publications/74925948-ACMG%202017%20Mundt%20variant%20classification%20Presented.pdf). This variant has been identified in 1/249592 chromosomes in the general population by the Genome Aggregation Database (gnomAD). In summary, this rare variant has been observed in multiple individuals and families affected with BRCA2-related phenotypes. Although additional studies are necessary to determine the role of this variant in disease and penetrance conclusively, this variant is classified as Likely Pathogenic based on the available evidence.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <NumberTested>108544</NumberTested>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972322dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0012933" />
          </Trait>
        </TraitSet>
        <Comment>This study involves interpretation of variants in research participants for the purpose of population health screening. Participant phenotype was not available at the time of variant classification. Additional details can be found in publication PMID: 35346344, PMCID: PMC8962531</Comment>
        <SubmissionNameList>
          <SubmissionName>SUB14382316</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="304022" SubmissionDate="2024-04-24" DateLastUpdated="2024-05-01" DateCreated="2014-08-06">
        <ClinVarSubmissionID localKey="a67738|MedGen:C0027672" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000185507" DateUpdated="2024-05-01" DateCreated="2014-08-06" Type="SCV" Version="8" SubmitterName="Ambry Genetics" OrgID="61756" OrganizationCategory="laboratory" OrgAbbreviation="Ambry" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17515903</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22921157</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23531862</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24312913</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">28152038</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29753700</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32341426</ID>
          </Citation>
          <Comment>The c.9672dupA pathogenic mutation, located in coding exon 26 of the BRCA2 gene, results from a duplication of A at nucleotide position 9672, causing a translational frameshift with a predicted alternate stop codon (p.Y3225Ifs*30). This alteration has been reported in multiple individuals and families with breast and/or ovarian cancer (van der Hout AH et al. Hum. Mutat. 2006 Jul;27:654-66; Reitsma W et al. Eur. J. Cancer 2013 Jan;49(1):132-41; Tea MK et al. Maturitas 2014 Jan;77(1):68-72; De Talhouet S et al. Sci Rep, 2020 04;10:7073). Further, this alteration was reported in trans with a likely pathogenic BRCA2 missense variant in a patient diagnosed with Fanconi anemia at 2 months of age, who later died of metastatic glioblastoma multiforme at age 4 (Dodgshun AJ et al. Cancer Genet. 2016 209(1-2):53-6). This alteration has also been detected in conjunction with another BRCA2 mutation in cells derived from a patient with Fanconi anemia (Howlett NG et al. Science 2002 Jul;297(5581):606-9; Feng Z et al. Proc. Natl. Acad. Sci. U.S.A. 2011 Jan;108(2):686-91). Of note, this alteration is also designated as 9900insA in published literature. In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation. As such, this alteration is interpreted as a disease-causing mutation. However, because this variant is identified in one or more patients with Fanconi Anemia it may be hypomorphic and thus, carriers of this variant and their families may present with reduced risks, and not with the typical clinical characteristics of a high-risk pathogenic BRCA2 alteration. As risk estimates are unknown at this time, clinical correlation is advised.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Ambry Variant Classification Scheme 2023</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/i9igeqse/ambry_variant_classification_scheme_2023.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0027672" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>All AVA3 Novel and Update Variants_103122</SubmissionName>
          <SubmissionName>FinalClinVarSubmissionFile_20140101to20240315_ava3_1</SubmissionName>
          <SubmissionName>NonExomeUpdate_081220AmbryReport</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1451246" SubmissionDate="2018-04-09" DateLastUpdated="2018-04-19" DateCreated="2018-04-19">
        <ClinVarSubmissionID localKey="NM_000059.3:c.9672dupA|OMIM:612555" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000744792" DateUpdated="2018-04-19" DateCreated="2018-04-19" Type="SCV" Version="1" SubmitterName="Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center" OrgID="506497" OrganizationCategory="laboratory" OrgAbbreviation="CGDx-EMC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2015-09-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACGS Guidelines, 2013</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/zo8lkdib/evaluation_and_reporting_of_sequence_variants_bpgs_june_2013_finalpdf.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="612555" Type="MIM" />
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB3885264</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1169507" SubmissionDate="2019-03-21" DateLastUpdated="2017-12-26" DateCreated="2015-10-11">
        <ClinVarSubmissionID localKey="70938403|Orphanet:ORPHA145" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000605805" DateUpdated="2017-12-26" DateCreated="2015-10-11" Type="SCV" Version="2" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-10-28">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17515903</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23531862</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24312913</ID>
          </Citation>
          <Comment>The p.Tyr3225fs variant in BRCA2 has been reported in the heterozygous state in &gt;30 individuals with BRCA2-associated cancers and in the compound heterozygous s tate in 1 individual with Fanconi anemia (Howlett 2002, Tea 2014, Hout 2006, Dru sedau 2013, Karami 2013, Breast Cancer Information Core (BIC) database). This va riant was absent from large population studies. This variant is predicted to cau se a frameshift, which alters the protein?s amino acid sequence beginning at pos ition 3225 and leads to a premature termination codon 30 amino acids downstream. Heterozygous loss of function of the BRCA2 gene is an established disease mecha nism in hereditary breast and ovarian cancer (HBOC). In summary, this variant me ets criteria to be classified as pathogenic for HBOC in an autosomal dominant ma nner.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LMM Criteria</Attribute>
          <Citation>
            <ID Source="PubMed">24033266</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>not provided</AffectedStatus>
              <FamilyData NumFamiliesWithVariant="1" />
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="1" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000059.3:EXON 27</GeneLocation>
          </Location>
          <OtherNameList>
            <Name>NM_000059.3:c.9672dupA</Name>
            <Name>p.Tyr3225IlefsX30</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972322_32972323insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA145" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB5348977</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3465589" SubmissionDate="2021-06-17" DateLastUpdated="2021-07-30" DateCreated="2021-07-30">
        <ClinVarSubmissionID localKey="report_configuration_variant_id:2359128" />
        <ClinVarAccession Accession="SCV001762267" DateUpdated="2021-07-30" DateCreated="2021-07-30" Type="SCV" Version="1" SubmitterName="Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen" OrgID="506385" OrganizationCategory="laboratory" OrgAbbreviation="IMGAG" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-06-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
              <NumberTested>1</NumberTested>
              <Gender>female</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="SampleLocalID">DX2102559</Attribute>
            </ObservedData>
            <TraitSet Type="Finding">
              <Trait Type="Finding" ClinicalFeaturesAffectedStatus="present">
                <XRef DB="HP" ID="HP:0003002" />
              </Trait>
            </TraitSet>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="TA" referenceAllele="T" start="32972321" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3836956" SubmissionDate="2021-09-30" DateLastUpdated="2021-10-02" DateCreated="2021-10-02">
        <ClinVarSubmissionID localKey=":Chr.13_32972321_32972321_T_TA|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001956712" DateUpdated="2021-10-02" DateCreated="2021-10-02" Type="SCV" Version="1" SubmitterName="Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+" OrgID="505925" OrganizationCategory="laboratory" OrgAbbreviation="Radboudumc_MUMC+" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506382" SubmitterName="Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen" Type="behalf" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="TA" referenceAllele="T" start="32972321" stop="32972321" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB10449206</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3991665" SubmissionDate="2021-12-16" DateLastUpdated="2021-12-18" DateCreated="2021-12-18">
        <ClinVarSubmissionID localKey=":Chr.13_32972321_32972321_T_TA|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002035341" DateUpdated="2021-12-18" DateCreated="2021-12-18" Type="SCV" Version="1" SubmitterName="Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)" OrgID="506395" OrganizationCategory="laboratory" OrgAbbreviation="LDGA" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="506382" SubmitterName="Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen" Type="behalf" OrganizationCategory="laboratory" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="13" alternateAllele="TA" referenceAllele="T" start="32972321" stop="32972321" variantLength="1" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <StudyName>VKGL Data-share Consensus</StudyName>
        <SubmissionNameList>
          <SubmissionName>SUB10812803</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1739074" SubmissionDate="2022-12-28" DateLastUpdated="2022-12-31" DateCreated="2017-12-19">
        <ClinVarSubmissionID localKey="S1362|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000889186" DateUpdated="2022-12-31" DateCreated="2017-12-19" Type="SCV" Version="3" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-06-17">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">22720145</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25103822</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">32341426</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">26740091</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25452441</ID>
          </Citation>
          <Comment>The BRCA2 c.9672dup (p.Tyr3225Ilefs*30) frameshift variant (also known as c.9672_9673insA and 9900insA) alters the translational reading frame of the BRCA2 mRNA and is predicted to cause the premature termination of BRCA2 protein synthesis. Although it is located in the last exon of BRCA2 and is not expected to undergo nonsense-mediated decay, the variant removes the last 194 residues of the BRCA2 protein including the RAD51-interaction region involved in recombination-mediated DNA repair (PMID: 17515903 (2007)). The frequency of this variant in the general population, 0.000004 (1/249592 chromosomes, http://gnomad.broadinstitute.org), is consistent with pathogenicity. In the published literature, the variant has been reported in individuals with breast and/or ovarian cancer (PMIDs: 32341426 (2020), 25452441 (2015), 25103822 (2014), 24156927 (2014)), as well as Fanconi anemia (PMIDs: 26740091 (2016), 22720145 (2012), 12065746 (2002)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12490872</SubmissionName>
          <SubmissionName>SUB4481696</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="7696427" SubmissionDate="2023-10-19" DateLastUpdated="2023-11-20" DateCreated="2023-11-20">
        <ClinVarSubmissionID localKey="23649809|BRCA2-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004119359" DateUpdated="2023-11-20" DateCreated="2023-11-20" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-20">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The BRCA2 c.9672dupA variant is predicted to result in a frameshift and premature protein termination (p.Tyr3225Ilefs*30). This variant has been reported in the heterozygous state in multiple individuals with breast and/or ovarian cancer (van der Hout et al. 2006. PubMed ID: 16683254; Karami et al. 2013. PubMed ID: 24312913; Tea et al. 2014. PubMed ID: 24156927; Couch et al. 2014. PubMed ID: 25452441; Rebbeck et al. 2018. PubMed ID: 29446198; Haer-Wigman et al. 2019. PubMed ID: 30291343). This variant has also been reported in the compound heterozygous or homozygous state in individuals with Fanconi anemia (Howlett et al. 2002. PubMed ID: 12065746; Barber et al. 2005. PubMed ID: 16115142). This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/13-32972321-T-TA) and is interpreted as pathogenic in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/126217/). Frameshift variants in BRCA2 are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000059.3:c.9672dupA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BRCA2-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13915440</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="470351" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2015-10-11">
        <ClinVarSubmissionID localKey="956756|MedGen:C0677776" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000255257" DateUpdated="2024-02-20" DateCreated="2015-10-11" Type="SCV" Version="11" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16683254</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24156927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29753700</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12065746</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17026620</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18593900</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18607349</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">22711857</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Tyr3225Ilefs*30) in the BRCA2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 194 amino acid(s) of the BRCA2 protein. This variant is present in population databases (rs80359773, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer, medulloblastoma, and Fanconi anemia (PMID: 12065746, 16683254, 24156927, 29753700). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is also known as 9900insA. ClinVar contains an entry for this variant (Variation ID: 126217). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects BRCA2 function (PMID: 12065746). This variant disrupts a region of the BRCA2 protein in which other variant(s) (p.Tyr3308*) have been determined to be pathogenic (PMID: 17026620, 18593900, 18607349, 22711857). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="BRCA2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000013.10:g.32972321_32972322insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0677776" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7696427" TraitType="Disease" MappingType="Name" MappingValue="BRCA2-related condition" MappingRef="Preferred">
        <MedGen CUI="CN239275" Name="BRCA2-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1414502" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="642938" TraitType="Disease" MappingType="Name" MappingValue="Not Provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="627268" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3465589" TraitType="Finding" MappingType="XRef" MappingValue="HP:0003002" MappingRef="HP">
        <MedGen CUI="C0678222" Name="Breast carcinoma" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="470351" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1169507" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA145" MappingRef="Orphanet">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3836956" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1361613" TraitType="Disease" MappingType="XRef" MappingValue="C0677776" MappingRef="MedGen">
        <MedGen CUI="C0677776" Name="Hereditary breast ovarian cancer syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="582455" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1779302" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1449982" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8353352" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1451246" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="502844" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="30143" TraitType="Disease" MappingType="Name" MappingValue="FANCONI ANEMIA, COMPLEMENTATION GROUP D1" MappingRef="Preferred">
        <MedGen CUI="C1838457" Name="Fanconi anemia complementation group D1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1148746" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007254" MappingRef="MONDO">
        <MedGen CUI="C0006142" Name="Malignant tumor of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7863313" TraitType="Disease" MappingType="XRef" MappingValue="114480" MappingRef="OMIM">
        <MedGen CUI="C0346153" Name="Familial cancer of breast" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3991665" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9032961" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0012933" MappingRef="MONDO">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3465589" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1553297" TraitType="Disease" MappingType="Name" MappingValue="Hereditary cancer-predisposing syndrome" MappingRef="Preferred">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1739074" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="264594" TraitType="Disease" MappingType="Name" MappingValue="Breast-ovarian cancer, familial 2" MappingRef="Preferred">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="304022" TraitType="Disease" MappingType="XRef" MappingValue="C0027672" MappingRef="MedGen">
        <MedGen CUI="C0027672" Name="Hereditary cancer-predisposing syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3746646" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5042042" TraitType="Disease" MappingType="XRef" MappingValue="612555" MappingRef="OMIM">
        <MedGen CUI="C2675520" Name="Breast-ovarian cancer, familial, susceptibility to, 2" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2021-11-13">SCV001854302</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

